<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">SMF</journal-id>
      <journal-title-group>
        <journal-title>Schweizerisches Medizin-Forum</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1424-4020</issn>
      <issn pub-type="ppub">1424-3784</issn>
      <publisher>
        <publisher-name>EMH Schweizerischer Ärzteverlag AG</publisher-name>
        <publisher-loc>Farnsburgerstrasse 8
CH-4132 Muttenz</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">09074</article-id>
      <article-id pub-id-type="doi">10.4414/smf.2022.09074</article-id>
      <article-categories>
        <!-- rubric -->
        <subj-group subj-group-type="Article Type">
          <subject>Der besondere Fall</subject>
        </subj-group>
        <!-- topics -->
        <subj-group subj-group-type="Classification">
          <subject>Allergologie / Immunologie</subject>
          <subject>Infektiologie</subject>
          <subject>Kardiologie</subject>
          <subject>Klinische Pharmakologie und Toxikologie</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Durchfall und Thoraxschmerzen in Zeiten der Pandemie</article-title>
      </title-group>
      <contrib-group>
        <contrib id="author-1" contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Stuby</surname>
            <given-names>Johann</given-names>
          </name>
          <email>johannstuby@aol.com</email>
          <aff>SWITZERLAND</aff>
        </contrib>
        <contrib id="author-2" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Eberhard</surname>
            <given-names>Matthias</given-names>
          </name>
          <email/>
          <aff/>
        </contrib>
        <contrib id="author-3" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Herren</surname>
            <given-names>Thomas</given-names>
          </name>
          <email/>
          <aff/>
        </contrib>
      </contrib-group>
      <pub-date pub-type="epub" date-type="pub" iso-8601-date="2022.10.26">
        <day>26</day>
        <month>10</month>
        <year>2022</year>
      </pub-date>
      <volume>22</volume>
      <issue>43</issue>
      <fpage>715</fpage>
      <lpage>717</lpage>
      <permissions>
        <copyright-statement>Copyright: EMH Schweizerischer Ärzteverlag AG</copyright-statement>
        <copyright-year>2022</copyright-year>
        <copyright-holder>EMH Schweizerischer Ärzteverlag AG</copyright-holder>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
          <license-p>"Swiss Medical Forum" is an open access publication of EMH published in accordance with the terms of the Creative Commons licence attribution - NonCommercial - NoDerivatives 4.0 International. You are free to share, copy and redistribute the material in any medium or format under the following terms:</license-p>
          <license-p>Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.</license-p>
          <license-p>NonCommercial — You may not use the material for commercial purposes.</license-p>
          <license-p>NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.</license-p>
          <license-p>"Non-commercial" means not primarily intended for or directed towards commercial advantage or monetary compensation. The incorporation of publications in commercial products, the use of publications to advertise for commercial products or services and any other usage that directly or indirectly pursues commercial interests is subject to the express previous consent of the publishing house as part of a written agreement.</license-p>
          <license-p>Please send us your request in writing. Exact indication of the publication from which you would like to reproduce material and detailed information about its intended use help to facilitate and expedite request processing.</license-p>
        </license>
      </permissions>
      <abstract abstract-type="article" xml:lang="de">
        <p>Das Spektrum der extra-intestinalen Manifestationen einer nicht-typhösen Salmonellen-Infektion ist gross, wobei die Myokarditis bisher nur vereinzelt beschrieben wurde. Die in der Literatur angegebene Mortalität ist hoch, da schwerwiegende Komplikationen wie Perikardtamponade, Ventrikelruptur oder Herzrhythmusstörungen ausgelöst werden können. Meist sind immunkompromittierte Personen betroffen, es können aber auch junge bis anhin gesunde Patienten daran erkranken. Die Therapie basiert auf einer optimalen Herzinsuffizienztherapie, bei schwerem Verlauf ist eine antibiotische Therapie zu evaluieren. In diesem Fallberichte entwickelte ein 23-jähriger Patient in der Folge einer Salmonellenenteritis eine Perimyokarditis. Zwei Wochen zuvor hatte er die erste Dosis eines COVID-19 mRNA-Impfstoffes erhalten, welche derzeit vermehrt mit Herzmuskelentzündungen in Verbindung gebracht werden.</p>
      </abstract>
    </article-meta>
  </front>
  <body/>
  <back/>
</article>
